A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry.

ABSTRACT:

Introduction

Patients with thoracic malignancies are at increased risk for mortality from coronavirus disease 2019 (COVID-19), and a large number of intertwined prognostic variables have been identified so far.

Methods

Capitalizing data from the Thoracic Cancers International COVID-19 Collaboration (TERAVOLT) registry, a global study created with the aim of describing the impact of COVID-19 in patients with thoracic malignancies, we used a clustering approach, a fast-backward step-down selection procedure, and a tree-based model to screen and optimize a broad panel of demographics and clinical COVID-19 and cancer characteristics.

Results

As of April 15, 2021, a total of 1491 consecutive eligible patients from 18 countries were included in the analysis. With a mean obs

SUBMITTER: Whisenant JG 

PROVIDER: S-EPMC8804493 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature